Aravive Investor Presentation Deck

Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure in P1b PROC Modeling Identified RP2D of 15 mg/kg for PROC Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile Exposure-response relationship identified by unsupervised computer analysis Statistically significant relationship between high trough concentrations and PFS >6 months Patients with higher exposures had more than doubling of PFS compared to 3 mos PFS paclitaxel historical control 1 Minimal efficacious concentration (MEC) of batiraxcept identified as 13.8 mg/L based on Akaike Information Criterion (AIC) Modeling predicts 15 mg/kg will provide increase in mPFS relative to 10 mg/kg but no further increase in mPFS with 20 mg/kg relative to 15 mg/kg RP2D of 15 mg/kg for PROC Efficacy Data for Patients Receiving 10 mg/kg and 15 mg/kg of Batiraxcept & Paclitaxel >MEC (N=10) 5 (50%), 2 CRs² ORR mPFS (months) mos (months)³ 7.5 19.0 <MEC (N=9) 2 (22%) 2.8 8.7 Taxol PL Reference ID: 2939751 21 patient 10mplig and 1 patent at 15mg/kg had CR, 1 patent at 15mpg with CR continued to show CR at C1301 while on braxcept alone, 5 months after discontinuing pace, and progressed after not receiving betraxcept for more than 2 weeks due to ness final mos pending trial completion DLT= dose-limiting toxicity, mos median overall survival MTD= maximum tolerated dose, mPFS = median progression free survival, ORR = overall response rate. RP2D recommended P2 dose 14

View entire presentation